These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 8093734

  • 1. Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT.
    Chumpradit S, Kung MP, Billings J, Mach R, Kung HF.
    J Med Chem; 1993 Jan 22; 36(2):221-8. PubMed ID: 8093734
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, in vitro binding profile and biodistribution of a 125I-labeled N-benzyl pyrrolidinyl benzamide derivative: a potential radioligand for mapping dopamine D2 receptors.
    Saji H, Tanahashi K, Kinoshita T, Iida Y, Magata Y, Yokoyama A.
    Nucl Med Biol; 1996 Feb 22; 23(2):121-7. PubMed ID: 8868283
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.
    Vessotskie JM, Kung MP, Chumpradit S, Romaniello G, McElgin W, Frederick D, Malison RT, Kung HF.
    J Nucl Med; 1995 Jul 22; 36(7):1282-8. PubMed ID: 7790957
    [Abstract] [Full Text] [Related]

  • 4. Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.
    Mukherjee J, Yang ZY, Das MK, Brown T.
    Nucl Med Biol; 1995 Apr 22; 22(3):283-96. PubMed ID: 7627142
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.
    Kessler RM, Votaw JR, de Paulis T, Bingham DR, Ansari MS, Mason NS, Holburn G, Schmidt DE, Votaw DB, Manning RG.
    Synapse; 1993 Nov 22; 15(3):169-76. PubMed ID: 8278895
    [Abstract] [Full Text] [Related]

  • 6. NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.
    Hall H, Högberg T, Halldin C, Köhler C, Ström P, Ross SB, Larsson SA, Farde L.
    Psychopharmacology (Berl); 1991 Nov 22; 103(1):6-18. PubMed ID: 1672460
    [Abstract] [Full Text] [Related]

  • 7. Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography.
    Halldin C, Högberg T, Farde L.
    Nucl Med Biol; 1994 May 22; 21(4):627-31. PubMed ID: 9234320
    [Abstract] [Full Text] [Related]

  • 8. Carbon-11 epidepride: a suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors.
    Langer O, Halldin C, Dollé F, Swahn CG, Olsson H, Karlsson P, Hall H, Sandell J, Lundkvist C, Vaufrey F, Loc'h C, Crouzel C, Mazière B, Farde L.
    Nucl Med Biol; 1999 Jul 22; 26(5):509-18. PubMed ID: 10473189
    [Abstract] [Full Text] [Related]

  • 9. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K, Toyama H, Nakashima H, Ichise M, Kurami M, Nakagawa T, Maeda H, Takeuchi A, Koga S.
    Kaku Igaku; 1994 May 22; 31(5):513-9. PubMed ID: 8028224
    [Abstract] [Full Text] [Related]

  • 10. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.
    Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen CT, Mintzer R, Cooper M.
    Nucl Med Biol; 1999 Jul 22; 26(5):519-27. PubMed ID: 10473190
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C, Scholz SW, Donnemiller E, Decristoforo C, Oberladstätter M, Stefanova N, Diederen E, Virgolini I, Poewe W, Wenning GK.
    Neuroimage; 2005 Feb 01; 24(3):822-31. PubMed ID: 15652317
    [Abstract] [Full Text] [Related]

  • 12. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.
    J Cereb Blood Flow Metab; 2001 Jan 01; 21(1):92-7. PubMed ID: 11149673
    [Abstract] [Full Text] [Related]

  • 13. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.
    Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A.
    J Nucl Med; 1990 May 01; 31(5):648-54. PubMed ID: 2140409
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and evaluation of high affinity, aryl-substituted [18F]fluoropropylbenzamides for dopamine D-2 receptor studies.
    Mathis CA, Bishop JE, Gerdes JM, Whitney JM, Brennan KM, Jagust WJ.
    Int J Rad Appl Instrum B; 1992 Jul 01; 19(5):571-88. PubMed ID: 1399687
    [Abstract] [Full Text] [Related]

  • 15. Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT.
    Mozley PD, Stubbs JB, Kim HJ, McElgin W, Chumpradit S, Kung MP, Romaniello G, Kung HF.
    J Nucl Med; 1995 Jul 01; 36(7):1322-31. PubMed ID: 7790963
    [Abstract] [Full Text] [Related]

  • 16. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
    Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M, Ackerhalt RE.
    Int J Rad Appl Instrum B; 1988 Jul 01; 15(2):195-201. PubMed ID: 2966782
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
    Hall H, Högberg T, Halldin C, Bengtsson S, Wedel I.
    Eur J Pharmacol; 1991 Aug 16; 201(1):1-10. PubMed ID: 1686586
    [Abstract] [Full Text] [Related]

  • 18. Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
    Kung HF, Kasliwal R, Pan SG, Kung MP, Mach RH, Guo YZ.
    J Med Chem; 1988 May 16; 31(5):1039-43. PubMed ID: 2966245
    [Abstract] [Full Text] [Related]

  • 19. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
    Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Munz DL, Emrich D, Rüther E.
    J Neural Transm Gen Sect; 1995 May 16; 99(1-3):187-93. PubMed ID: 8579804
    [Abstract] [Full Text] [Related]

  • 20. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
    Högberg T, Ström P, de Paulis T, Stensland B, Csöregh I, Lundin K, Hall H, Ogren SO.
    J Med Chem; 1991 Mar 16; 34(3):948-55. PubMed ID: 1672158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.